Mark James Litton, CEO at Athira Pharma, Inc. (ATHA), sold 4,820 shares at $2.91 ($14K) on 2024-01-05, disclosed to the SEC on 2024-02-16.
Open-market sale of $14k ATHA by CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| ATHA | SELL | 2025-07-02 | $7K | — | Filing → |
| ATHA | SELL | 2025-01-03 | $14K | — | Filing → |
| ATHA | SELL | 2024-09-05 | $3K | — | Filing → |